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ABSTRACT: Antibody-drug conjugates (ADCs) represent a fast growing class of biotherapeutic products. Their pro-
duction leads to a distribution of species exhibiting different number of conjugated drugs overlaying the inherent 
complexity resulting from the monoclonal antibody format, such as glycoforms. ADCs require an additional level 
of characterization compared to first generation of biotherapeutics obtained through multiple analytical tech-
niques for complete structure assessment. We report the development of complementary approaches implement-
ing sheathless capillary electrophoresis-mass spectrometry (sheathless CE-MS) to characterize the different as-
pects defining the structure of brentuximab vedotin. Native MS using sheathless CE-MS instrument as a nanoESI 
infusion platform enabled accurate mass measurements and estimation of the average drug to antibody ratio 
alongside to drug load distribution. Middle-up analysis performed after limited IdeS proteolysis allowed to study 
independently the light chain, Fab and F(ab’)2 subunits incorporating 1, 0 to 4 and 0 to 8 payloads respectively. 
Finally, a CZE-ESI-MS/MS methodology was developed in order to be compatible with hydrophobic drug compos-
ing ADCs. From a single injection, complete sequence coverage could be achieved. Using the same dataset, glyco-
sylation and drug-loaded peptides could be simultaneously identified revealing robust information regarding their 
respective localization and abundance. Drug-loaded peptide fragmentation mass spectra study demonstrated 
drug specific fragments reinforcing identification confidence, undescribed so far. Results reveal the method ability 
to characterize ADCs primary structure in a comprehensive manner while reducing tremendously the number of 
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experiments required. Data generated showed that sheathless CZE-ESI-MS/MS characteristics position the meth-
odology developed as a relevant alternative for comprehensive multilevel characterization of these complex bio-
molecules.   
1. INTRODUCTION 
Antibody-drug conjugates (ADCs) are an emerging category of biotherapeutic products, derived from monoclonal 
antibodies (mAbs)[1], they combine the high anti-cancer potency of cytotoxic drugs to the exquisite selectivity 
and favorable pharmacological properties of mAbs and are obtained through chemical linkage [2]. In addition to 
the recent approval by the US Food and Drugs Administration (FDA) of brentuximab vedotin (Adcentris, Seattle 
Genetics) and trastuzumab emtansine (Kadcyla, Genentech/ Roche), more than 50 ADCs are currently investi-
gated in clinical trials indicating the broad interest of the biopharmaceutical industry for this type of treatments 
[3, 4]. ADCs incorporate highly potent warheads which can be delivered using the specificity provided by mAbs to 
target tumor cells and limit exposition of healthy cells therefore optimizing treatment potency and limit the oc-
currence of side effects [5]. 
Drug conjugation can be implemented through different chemical reactions depending on the amino acid residue 
or glycan concerned [6]. Especially, drug coupling using the lysine residue’s amino group and cysteine residues 
through thiol group after reduction of disulphide bridges have been reported[7, 8]. Drug conjugation reaction 
leads to the production of a mixture of different species showing various numbers of drugs conjugated to the 
protein. While for a single species, drugs can still be distributed in various manner on the different conjugation 
sites. This complexity is reflected by parameters such as the drug loading and distribution, the amount of naked 
antibody (D0) and the average number of drug to antibody (DAR). These three parameters are critical quality 
attributes (CQAs) for ADCs because they impact on safety, pharmacokinetics (PK) and pharmacodynamics (PD) 
[9].  
ADCs heterogeneity generated from different number and position of conjugated drugs during production is com-
bining to the intrinsic variability coming from conjugation with mAbs. mAbs are complex glycoproteins exhibiting 
a consequent number of micro-heterogeneities which can influence significantly antibody-dependent cell-medi-
ated cytotoxicity (ADCC) and complement-dependent cytotoxicity of the considered mAb  [10, 11]. Currently a 
large panel of analytical techniques are required in order to perform a comprehensive structural characterization 
of biotherapeutic proteins including ADCs [12]. Mass spectrometry (MS) has gradually taken a decisive position in 
structure characterization of biopharmaceutical products [13-16], likewise ADCs, mainly due to an outstanding 
selectivity allowing the identification of the different species composing ADCs samples and the opportunity to 
obtain structural information [17]. MS still often needs to be used in concomitance with separation methods 
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mainly including liquid chromatography [18, 19]. Recently, we described a method using capillary zone electro-
phoresis (CZE) coupled to tandem MS with a sheathless interface to perform the simultaneous characterization 
of several aspects of a protein in one injection including amino acid sequence, glycosylation characterization and 
other types of posttranslational modifications (PTMs) [20-22]. 
In this work, we report the development of a combined approach implementing a sheathless capillary electro-
phoresis (CE) interface used as nanoESI infusion platform or as separation method, hyphenated to tandem MS 
(MS/MS) for the detailed structural characterization of different traits composing the primary structure of ADCs. 
The ADC considered is brentuximab vedotin (BV) which has been approved in 2011 by the FDA and consequently 
by the European Medicine Agency (EMA) for the treatment of Hodgkin Lymphoma and systemic anaplastic large 
cell lymphoma[7, 23]. It is composed of the tubulin inhibitor monomethyl auristatin E (MMAE) conjugated to the 
chimeric mAb cAC10 via a protease cleavable maleimidocaproyl-valine-citrulline-((p-aminobenzyl)oxy)carbonyl 
linker (MC-PV-PABC) by reduction of the interchain disulfide bonds [7, 24]. The presence of the cysteine linked 
MMAE does not disrupt the interchain disulfide bonds between the heavy chain (Hc) and (Lc) of the mAb which 
allows to maintain the higher order structure of the protein and therefore its specificity for the targeted antigen 
[25, 26].  
As the first level of characterization, we evaluated the sheathless CE-MS system as nanoESI infusion platform for 
native MS determination of the average DAR of BV and to obtain the drug load distribution. In a second step, to 
further investigate the characterization of BV using the instrument setting, we realized the middle-up analysis of 
BV by IdeS proteolysis. IdeS enzymatic reaction cleaves ADC between the two consecutive glycine residues pre-
sent in the hinge region to obtain two types of fragments (Fc/2 and F(ab’)2). Finally, a sheathless CE-MS/MS method 
derived from bottom-up proteomic analysis was developed in order to be fully compatible to the requirement of 
the analysis of ADCs. Analysis of BV was performed by sheathless CZE-ESI-MS/MS enabling the simultaneous char-
acterization of the amino acid sequence of the ADC alongside to the characterization of glycoforms as well as 
drug-loaded peptides giving precious information regarding the drug effectively conjugated to the mAb. 
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2. MATERIALS AND METHODS 
2.1 Materials. Chemicals used were of analytical grade or high purity grade and purchased from Sigma-Aldrich 
(Saint Louis, MO, USA). Water used to prepare buffers and sample solutions was obtained using an ELGA purelab 
UHQ PS water purification system (Bucks, UK). RapiGest SF surfactant was purchased from Waters (Milford, MA, 
USA). IdeS (immunoglobulin degrading enzyme of Streptococcus pyogenes) also named FabRICATOR was pur-
chased from Genovis (Lund, Sweden). Brentuximab vedotin (Adcetris®) was produced by Millenium Pharmaceuti-
cals/Takeda (London, UK). 
2.2 Intact ADC sample preparation. Brentuximab vedotin (BV) was buffer exchanged with 200 mM ammonium 
acetate buffer, pH 7.0 using Amicon centrifugal filters (cut off = 10,000 Da) (Merck Millipore, Darmstadt, Germany). 
Six desalting step were performed at 10°C and 14,000×g for 20 min each step. Ammonium acetate allows the 
native structure of proteins to be preserved and be compatible to ESI-MS.  
2.3 ADC IdeS digestion. BV was cleaved in the hinge region using proteolysis by IdeS (FabriCATOR, Genovis) to 
obtain two Fc/2 fragments and one F(ab’)2 fragment. Sample was diluted using 147.25µL of 50 mM sodium phos-
phate, 150 mM NaCl, pH 7.4, to a final concentration of 1 µg/µL. A volume of 2.25 µL of IdeS (67 units/µL) was 
added to the sample which was left at 37°C for 30 min. After digestion completion, sample was buffer exchanged 
with 200 mM ammonium acetate buffer, pH 7.0 using Amicon centrifugal filters (cut off = 10,000 Da) at 10°C and 
14,000×g for 20 min.  
2.4 In solution protein digestion. Prior to tryptic digestion, BV was cleaved by IdeS following the ADC IdeS di-
gestion protocol. After IdeS digestion completion, sample was buffer exchanged using three desalted cycles 
(Amicon centrifugal filters, 10,000 cutoff) with 50 mM ammonium bicarbonate buffer, pH 8.0 at 4°C and 14 000g 
for 20 min. Theoretical concentration of 12.5 µg/µL was obtained by reducing sample volume to 10 μL. Sample 
were then diluted using 0.1% RapiGest surfactant to a final concentration of 6.25 µg/µL and heated to 40°C during 
10 min. Dithiothreitol (DTT) was added to the sample in order to obtain a final concentration of 25 mM. Samples 
were then heated to 80°C during 10 min. After being cooled down to room temperature (RT), 10% of acetonitrile 
was added to the sample. A volume of 2 µL of trypsin (0.5µg/µL) was added to the sample which was left at room 
temperature for 3h, another volume of 2 µL was added afterward. Digestion was performed overnight at 37°C. A 
second reduction step was performed by addition of DTT to a final concentration of 35 mM and heated for 45 min 
at 56°C. Then 40% of isopropanol was added to the sample. After digestion completion, formic acid (FA) was added 
to a final concentration of 1% (v/v) in order to cleave the surfactant. Sample was left at RT for 2h. Sample was 
finally diluted to a final concentration in protein of 2.2 µM using ammonium acetate 50 mM, pH 4.0. 
2.5 Capillary electrophoresis. CE experiments and NanoESI infusion experiments were performed with a 
CESI8000 capillary electrophoresis system from Sciex Separation (Brea, CA, USA). Bare fused-silica capillaries (total 
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length 100 cm; 30 μmi.d.) with characteristic porous tip on its final end on 3 cm, a second capillary (total length 
80 cm; 50 μmi.d.) filled during experiments with BGE allows electric contact. New capillaries were flushed for 10 
min at 75 psi (5.17 bar) with methanol, then 10 min with 0.1 M sodium hydroxide, followed 10 min with 0.1 M 
hydrochloric acid and water for 20 min also at 75 psi. Finally, the capillary was flushed 10 min at 75 psi with BGE 
which was 10% acetic acid. For nanoESI experiments, capillary was flushed for 5 min at 50 psi (3.45 bar) with 10% 
acetic acid, then 5 min with sample. After measurement, capillary was flushed for 10 min at 50 psi (3.45 bar) with 
10% acetic acid. No carry over between each measurement were observed with this method. For CE experiments, 
hydrodynamic injection (10 psi for 1 min) corresponding to a total volume of 90 nL of sample injected was used. 
Separations were performed using a voltage of +20 kV. For infusion experiments, sample was flushed into the 
capillary at 50 psi for 3 min. The infusion was carried out by flushing sample at 5 psi for 5 min corresponding to a 
total volume of 245 nL of sample. 
2.6 Mass spectrometry. For ADC peptide mapping characterization, the CESI8000 system was hyphenized to a 
Triple TOF 6600 mass spectrometer (Sciex, Darmstadt, Germany). The TripleTOF 6600 MS is equipped with a hybrid 
analyzer composed of a quadrupole followed by a time-of-flight (TOF) analyzers. ESI source parameters was set as 
follow: ESI voltage -1.45kV while Gas supplies (GS1 and GS2) were deactivated, source heating temperature 150°C 
and curtain gas value 4. Mass/charge (m/z) range was 100-2000 in MS and 50-2000 in MS/MS. External calibration 
was performed using a digest of β-galactosidase from Sigma-Aldrich (Saint-Louis, MO, USA). For ADC NanoESI in-
fusion experiments, the CESI8000 system was coupled to a maxis 4G (Bruker Daltonics, Bremen, Germany). MS 
transfer parameters were optimized using the actual sample directly infused via the CE system using a pressure of 
5 psi (340 mbar). Ion funnels were set at values of 300 and 400 Vpp. The electrospray voltage (capillary voltage) 
typically ranged from −1.2 to −1.8 kV. Dry gas was set at 1.5 L/min and source temperature at 180 °C. Data pro-
cessing was performed with DataAnalysis 4.0. Deconvolution of the mass spectra was performed on the basis of 
maximum entropy analysis using ESI Compass 1.3 Maximum Entropy Deconvolution Option. All spectra were cali-
brated by external calibration using CsI from Sigma-Aldrich (Saint-Louis, MO, USA). 
2.7 MS/MS data analysis. Data obtained from the sheathless CE-MS/MS experiments were analyzed using Peak-
view and BioParmaView software (Sciex, San Francisco, CA). The mass tolerance allowed for search algorithm 
identification, for precursor ions was set to ± 5 ppm and ±0.05 Da for fragmentation ions.  
2.8 Drug-to-Antibody Ratio (DAR) determination. Average DAR values are calculated from the relative peak 
area of each peak from the charge state deconvoluted mass spectrum. Average DAR value is obtained following 
the equation: 
𝐷𝐴𝑅 =
∑𝑛𝐴𝐷𝑟𝑢𝑔
∑𝐴𝐷𝑟𝑢𝑔
 
With n the number of drug loads ranging from 0 to 8. 
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3. RESULTS AND DISCUSSION 
3.1 Average DAR determination using sheathless CE-MS Interface as a nanoESI emitter 
For the first level of the characterization of ADCs, we determined the average DAR of BV and we assessed the 
drug load distribution by native MS on a high resolution Q-TOF instrument using sheathless CE-MS interface as a 
nanoESI emitter (Figure 1-a). In a recent work, we demonstrated the suitability of sheathless CE-MS system to be 
used as nanoESI infusion platform [27]. Benefits of nanoESI as the lower source temperature and spraying voltage, 
the increase of sensitivity and the decrease of ion suppression phenomenon make this interface a particularly 
suitable system for biotherapeutic characterization.  To achieve optimal MS resolution and sensitivity, BV was sys-
tematically desalted before infusion removing any components in the formulation buffer that can affect the sta-
bility of the spray. Within a single run of 5 min at a flow rate of 50 nL/min which represent an infused sample 
volume of 250 nL, we obtained a distribution of baseline resolved species of BV (Figure 1-a) with masses corre-
sponding to the intact mAb linked with zero to eight payloads (Table S-1). Mass accuracies on intact BV using Q-
TOF instrument is in total agreement with results reported in the literature [15, 26]. As expected, no detection of 
ions corresponding to dissociated BV, referring to free drug loaded Lc or Hc formed during the ionization or the 
ion transfer inside the mass spectrometer,  were observed confirming that the combination of sheathless CE-MS 
interface with native MS enhances the detection of drug load species and allows to obtain the drug-load distribu-
tion. Based on charge state deconvoluted mass spectrum of intact and deglycosylated BV, average DAR value of 
3.8 and 3.9 respectively were calculated using the relative quantification from the peak area of each peak and the 
corresponding number of drugs loaded. Obtained average DAR values are in good agreement with values de-
scribed in the literature [15, 26] [25]. It demonstrated the ability of the sheathless CE-MS system used as nanoESI 
infusion platform to get structural information of intact BV within a single run and consuming in total less than of 
3µg of ADC samples.  
 
 
 
 
 
 
 
7 
 
 
Figure 1. Overview of brentuximab vedotin structural characterization using sheathless CE-MS. (a) Native MS in-
fusion for average DAR determination and drug loaded distribution assessment, (b) middle-up and bottom-up 
analysis.  
 
3.2 Middle-up analysis of brentuximab vedotin 
Dozens of recent reports from the FDA, Industry and academic clearly show that to extensively characterize large 
biopharmaceuticals such as mAbs, ADC, biosimilars to name a few, consistent data must be reported at multiple 
levels [28-36] . To investigate deeper the structure of BV using the same system, we performed the middle-up 
analysis of BV by IdeS proteolysis. Middle-up refers to the mass measurements of large fragments of proteins after 
proteolysis[29]. IdeS is a cysteine endopeptidase enzyme naturally secreted by Streptococcus pyogenes[37], IdeS 
enzymatic reaction cleaves specifically immunoglobulin G (IgG) between the two consecutive glycine residues pre-
sent in the hinge region (Figure 1-b). IdeS cleavage results in two fragments (Figure 1-b) : Fc/2 domain carrying a 
N-glycosylation site in the Asn 297 with a mass of approximately 25 kDa (Table S-1) depending on the glycoform 
and F(ab)’2 domain potentially linked by zero to eight payloads with masses of approximately 97 kDa to 108 kDa 
(Table S-1). Following the same protocol used for intact ADC, within a single run of 5 min at a flow rate of 50 
nL/min, we obtained a raw MS data with three main charge envelope profiles (Figure 2-a). The resulting most 
intense charge envelope between m/z 2000 and 3300 (Figure 2-b) corresponds to the light chain (Lc) with the 
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incorporation of one payload (Mw = 25040.1 ± 0.1 Da). Of note, two glycations corresponding to a difference of 
mass of 162 Da were characterized (Figure 2-b1). 
 
Figure 2. (a) MS spectra corresponding to Native MS NanoESI infusion of middle-up brentuximab vedotin. (b) 
Charge state deconvoluted mass spectra of (1) Lc-drug conjugated subunit, (2) Fab subunits with the incorporation 
of  0 to 4 payloads and Fc/2 homodimers and (c) F(ab)’2 subunits with the incorporation of 0 to 8 payloads. 
 
The second part of the raw data matching to the most intense charge envelope between m/z 3500 and 4800 
corresponds to two different subunits of the BV. First, as shown in Figure 2-b2, the measured masses correspond 
to the Fab domain linked by zero to four payloads (Table S-1). This confirms that, even in native condition, IdeS 
reaction affects BV with the partial loss of noncovalent interaction certainly due to the hydrophobicity of the drug 
whose the chemical impact is greater on 100 kDa subunits as compared to intact ADC. In second way, deconvo-
luted mass spectra also generated multiple masses between 50.4 kDa to 50.8 kDa (Figure 2-b2). These peaks cor-
respond to the formation of protein-protein aggregates due to noncovalent interactions between Fc/2 subunits. 
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Indeed, mass peak 50400 ± 1 Da correspond to the mass of Fc/2 subunits homodimer bearing two G0F glycosylation 
(Table S-2).  
 
Figure 3. (a) Base Peak Electropherogram corresponding to the analysis by CESI-MS of brentuximab tryptic digest. 
(b) Extracted Ion Electrophorogram (EIE) corresponding to the m/z ratios of [EYK] and 
[DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTK]. MS/MS fragmentation spec-
tra for both peaks (right-hand side). (c) EIE of m/z ratios 780.11 and 1039.81 ([TKPREEQYNSTYR] + G0F) and corre-
sponding MS/MS fragmentation spectra (right-hand side). 
 
 
Other mass peaks between 50.4 kDa and 50.8 kDa correspond to the expected presence of the combination of 
neutral glycosylation variants of this dimer (Table S-1). In addition, no deconvoluted mass spectrum have been 
observed at 25 kDa that excludes the presence of free Fc/2 variants in ammonium acetate 200mM at pH 7.0. To our 
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knowledge, this is the first time that non-covalent dimers of ADC Fc/2 subunits have been observed and character-
ized. Finally, the third profile of the raw data (Figure 2-a) corresponding to the most intense charge envelope 
between m/z 5000 to 6000 is in agreement with the theoretical masses of  F(ab’)2 subunits with the incorporation 
of 0, 2, 4, 6 and 8 payloads (Figure 2-c3 and Table S-1). The profile obtained for the middle-up analysis shows that 
IdeS digestion generates for the same part of the protein different kind of fragments which is illustrated for exam-
ple by the detection of free Lc and F(ab’)2 incorporating also the Lc of the ADC. Therefore the mixture generated 
from the limited digestion did not allow to estimate a satisfying DAR value justifying the intact analysis described 
previously. However IdeS proteolytic digestion still remains relevant in order to study specific traits defining the 
structure of therapeutic proteins due to the lowered and distinctive m/z range, especially to evaluate the efficiency 
of the coupling reaction for each proteolytic fragment. Therefore MS resolution and mass accuracy is improved 
supported by the increase of sensitivity and the decrease of ion suppression phenomenon provided by the nanoESI 
infusion demonstrated the ability of the sheathless CE-MS system to obtained structural information of BV after 
proteolysis. 
 
3.3 Primary structure characterization of brentuximab vedotin. 
MS based bottom-up analysis is commonly used to determine protein amino acid sequence and to locate or 
quantify PTMs. For primary structure characterization (Figure 1-c), this methodology is particularly crucial in early 
development of therapeutic antibodies as well as during long-term life cycle management of the biopharmaceu-
tical products [38]. As part of this work, one of the objectives was to investigate the possibility to perform robust 
and confident peptide mapping of BV by sheathless CZE-ESI-MS/MS.   
BV was characterized in a bottom-up proteomic adapted strategy, samples were digested by trypsin using an in 
solution digestion protocol. Recently, we described a method using sheathless CZE-ESI-MS to perform the simul-
taneous characterization of several aspects of a mAb in one injection including amino acid sequence and in comi-
tance several types of PTMs [20, 39]. However, for the BV analysis, the intensity of some peptide signals on the 
electropherogram was low or non-existent due to the presence of hydrophobic drug-loaded-peptides. More re-
cently, Janin-Bussat et al. described the first Lys-C digestion protocol for the characterization of drug-loaded-pep-
tides of ADC by LC-MS analysis. They improved the classical protocol by several steps of reduction, fractionation, 
enrichment and addition of organic solvent during the digestion protocol to maintain the drug-loaded peptides in 
solution [18]. Taking that into account and to enhance the level of characterization especially regarding ADCs 
amino acid sequence, glycoforms and drug-loaded-peptides, the sample treatment was adapted for trypsin diges-
tion while still compatible with the electrophoretic separation, and modified with the elimination of the enrich-
ment and LC collection steps. Briefly, prior to trypsin digestion protocol, IdeS enzymatic reaction was performed 
to cleave BV between the two consecutive glycine residues present in the hinge region to obtain the Hc peptide 
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[THTCPPCPAPELLG] which can be conjugated by one or two payloads. After IdeS digestion completion, sample was 
buffer exchanged against 50 mM ammonium bicarbonate buffer, pH 8.0. Before trypsin digestion, 10% of acetoni-
trile was added to the sample and 40% of isopropanol after digestion [18]. Sample was finally diluted to a final 
concentration in protein of 2.2 µM using ammonium acetate 50 mM, pH 4.0. BV digests were analyzed through 
sheathless CZE-ESI-MS/MS with an injection volume corresponding to a quantity of 200 fmol of digested peptides.  
The total duration of the separation was less than 35 min and the resulting electropherogram showed that all 
peptides were detected between 14 to 28 min (Figure 3-a). The tremendous efficiency of CZE separation allows 
peak widths at half height ranging from 0.15 min down to 0.8 min representing a number of theoretical plates 
ranging from 200000 up to 600000 plates. Digested peptides were analyzed by MS/MS enabling to characterize in 
a single injection the complete sequence coverage of BV. These results confirm the absence of any detrimental 
effect due to the modification of the enzymatic proteolysis protocol on the amino acid sequence characterization 
compared to previously published results [20]. The presence of organic solvent during reduction and digestion 
steps did not prevent the electrophoretic separation and detection of tryptic peptides regardless of their proper-
ties. Indeed, tryptic digestion produces a heterogeneous mixture of peptides, especially with regard to their num-
ber of amino acids. The identification during the analysis of very small peptide of 3 amino acids are observed 
alongside to a 63 amino acids peptide having a molecular mass of 6656.29 Da (Figure 3-b). Additionally, peptide 
identification was based on both peptide mass measurement and fragmentation products using MS/MS spectra 
in order to enable unambiguous characterization. Results demonstrate the possibility to perform characterization 
of ADCs amino acid sequence using the sheathless CZE-ESI-MS/MS method developed advanced and using only a 
single injection of 200 fmol of digested BV peptide mixture.   
 
 
3.4 Characterization of brentuximab vedotin N-glycosylation. 
ADCs are glycosylated proteins and those glycans are naturally incorporated in the protein during secretion into 
the extracellular environment [6]. BV is N-glycoslylated on the Asn 297 in the CH2 region. The excellent ionization 
efficiency provided by sheathless CZE-ESI-MS allows detection of glycopeptides with significant intensities, gener-
ating good quality MS/MS identification of even lowly abundant species. N-glycosylation characterization of BV 
was performed using the same data sets used for peptide mapping. In the case of BV, the extracted ion elec-
tropherograms (XIE) of the m/z ratio matching to the peptide TKPREEQYN297STYR bearing 11 glycosylations were 
observed (Table S-2). Identifications were based on accurate mass measurement in MS1 (Figure 3-c) provided by 
high resolution MS and additionally fragmentation spectra. MS/MS spectra corresponding to the fragmentation 
of the different glycopeptides were subsequently extracted from the data. As expected with low energy collision 
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induced dissociation (CID), product ions observed in MS/MS mainly correspond to the fragmentation of the glycan 
moiety. Very low intense b ions fragment can be observed but the peptide backbone is usually preserved (Figure 
3-c). All detected glycopeptides have a charge state of 3 and 4. The similarity of the glycoforms characterization 
of BV in terms of number of glycosylation and MS/MS quality spectra as compared to the mAb characterization 
previously described [20], allows to conclude that the modification of the enzymatic protocol, especially the pres-
ence of acetonitrile and isopropanol did not affect the characterization of glycopeptides.      
 
Figure 4. MS and MS/MS spectra of drug-loaded peptides. (a) [GEC] + 1 payload, (b) [SCDK] + 1 payload, (c) 
[THTCPPCPAPELLG] + 1 payload and (d) [THTCPPCPAPELLG] + 2 payloads  
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3.5 Identification of drug-loaded-peptide of BV 
The final aim of this work was to propose a methodology using CZE-ESI-MS/MS allowing to obtain structural 
information of ADCs especially regarding drug-loaded-peptides. The major issue concerning the characterization 
of drug-loaded-peptide is based on their hydrophobic properties because of the presence of the conjugated drug 
[26]. Using the protocol we developed in a previous work for the characterization of mAbs based on an aqueous 
solution trypsin digestion  [20], no or very low intensity of these modified peptides was observed due to a possible 
precipitation during the reduction or digestion steps. Hydrophobic drug-loaded peptides generated from the tryp-
tic digestion of BV could be successfully maintained in solution by incorporating acetonitrile and isopropanol in 
the sample preparation. These peptides could be successfully identified (Figure 4). Each peptide were character-
ized based on accurate mass measurement in MS1 provided by high resolution MS and additionally by the char-
acteristic in-source fragmentation ions (m/z 718.51) described by Junutula et al [40] and also with seven additional 
diagnostic ions (m/z 686.49, 506.36, 411.26, 321.21, 170.11, 152.10, 134.09) observed in all MS/MS spectra of 
molecules containing MMAE (Figure 4). As glycopeptide characterization, product ions, observed in MS/MS with 
low energy CID, mainly correspond to the fragmentation of the MMAE moiety. Very low y ion fragment can be 
observed but the peptide backbone is usually preserved. However, while glycopeptide MS/MS spectra allow to 
detect ions corresponding to fragments of glycopeptide, drug-loaded-peptide MS/MS spectra only allow to detect 
the fragmentation of the drug. This makes it necessary to have a few signing ions on the MS/MS spectrum to 
characterize those peptides without ambiguity. The seven diagnostic ions have been identified by a molecular 
modeling study using Mass Spec Calculator Pro (BCP Instrument, France). Figure 5 shows the structures of MMAE 
fragments matching with the theoretical masses detected in all drug-loaded-peptides MS/MS spectra.  
Using the same set of data, we identified four different drug-loaded-peptides. Peptides presented a [M+2H] 
mass of 812.44 (Figure 4-a) and a [M+2H] of 884.99 (Figure 4-b), were corresponding the theoretical masses of 
the Lc peptide [GEC] and the Hc peptide [SCDK] both conjugated to 1 payload. The peptide corresponding to m/z 
918.15 exhibiting a charge state of 3+ (Figure 4-c) was consistent to the Hc peptide [THTCPPCPAPELLG] conjugated 
to 1 MMAE molecule. Finally, the peptide presented a [M+4H] mass of 1018.06 was compatible the Hc peptide 
[THTCPPCPAPELLG] conjugated to 2 payloads. For [GEC] and [SCDK], Cys 218 and Cys 220 are involved in the disul-
fide bond with the Lc peptide and the Hc peptide respectively, while for [THTCPPCPAPELLG] Cys 226 and Cys 229 
are involved in the disulfide bonds between the two Hc. Those results confirm the characterization of the expected 
drug-loaded-peptides linked to the inter-chain cysteines of the Hc and Lc [18]. The capacity to separate peptides 
having payload is clearly interesting because they tend to compete against each other during the ionization pro-
cess, potentially interfering with relative quantification. Using the sheathless CZE-ESI-MS/MS methodology, the 
m/z ratios corresponding to the native peptide and the peptide incorporating 1 or 2 payloads (Table 1) migrate as 
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two different peaks separated by several minutes. In the context of characterization of BV, results of relative quan-
titation allowed to estimate site by site the yield of drug incorporation (Table 1). To evaluate the robustness of this 
method, the analysis was repeated six times and considered as technical replicates, allowing us to obtain equiva-
lent results. The same data were used for MS/MS peptide mapping, glycoforms and drug-loaded-peptide charac-
terization without requiring additional experiments. Results detailed in this section clearly shows the ability using 
sheathless CZE-ESI-MS/MS analysis to perform a site specific localization study of the conjugation between the 
mAb and the drug employed giving additional information required in the development pipeline of ADCs therefore 
completing the primary structure characterization of this type of therapeutic proteins.    
 
 
Figure 5. Schematic structures of brentuximab vedotin and characteristic fragments of MMAE payload 
 
4. CONCLUSION 
To summarize, we report here the implementation of new analytical approaches based on a sheathless capillary 
electrophoresis (CE) interface used as nanoESI infusion platform or as separation method, hyphenated to tandem 
MS for the detailed and rapid structural characterization of a gold standard ADC. Starting with an intact ADC native 
15 
 
MS study (top level) and going through middle-up and then bottom-up MS approach, we were able to characterize 
BV from intact mass measurement to the amino acid sequence level. At the intact ADC level, we evaluated sheath-
less CE-MS system used as nanoESI infusion platform for native MS determination of the average DAR and drug 
load distribution of BV. We show native sheathless CE-MS is applicable to interchain cysteine-linked ADCs without 
any detrimental effect on the noncovalent structure. Within a single run of few minutes and consuming less than 
of 3µg BV sample, calculated DAR value were in good agreement with already published values. To investigate 
deeper the characterization of BV, middle-up analysis using IdeS enzymatic digestion has been performed follow-
ing the same experimental protocol used for intact BV analysis. Structural information of the expected Fc/2 subunits 
and F(ab’)2 subunits with the incorporation of zero to eight payloads have been obtained. Additionally, other 
subunits as Lc conjugated to one payload and Fab conjugated to zero to four payloads have been observed and 
characterized. Of note, regarding native MS analysis of Fc/2, results showed the formation of Fc/2 non-covalent 
dimers following BV IdeS treatment. To the best of our knowledge, this is the first time that non-covalent dimers 
of ADC Fc/2 subunits have been observed and characterized. Finally, we report here the use of sheathless CZE-ESI-
MS/MS for the bottom-up analysis of BV to enhance the level of characterization, especially regarding amino acid 
sequence, glycoforms and drug-loaded-peptides. Using a single injection of 200 fmol, we were able to characterize 
the primary structure of those conjugates in a robust manner. We managed to perform the complete amino acid 
sequence characterization. Simultaneously, using the same set of data, glycosylations and drug-loaded-peptides 
were also characterized. Concerning glycosylation, 11 different N-glycans could be characterized for BV, confirming 
the advantages of using sheathless CZE-ESI-MS improved sensitivity. Regarding the drug-loaded-peptides, we iden-
tified four drug-loaded-peptides linked to the inter-chain cysteines of the Hc and Lc which gave precious infor-
mation regarding the localization of the conjugated drugs on the studied ADC and the assessment of the yield of 
drug incorporation. In order to characterize unambiguously these drug-loaded-peptides, seven diagnostic ions 
have been identified and structurally characterized as MMAE fragments present in MS/MS fragmentation spectra. 
The CZE-ESI-MS/MS data reported here indicate that electrophoretic separation, combined to the highly efficient 
sheathless CE-MS interface become a relevant alternative to LC-ESI-MS/MS for innovative approaches in MS for 
the characterization of a large panel of highly complex biotherapeutics. 
 
Acknowledgments 
Authors would like to thank Sciex separations Inc. for lending a CESI8000 system and a 5600 TripleTOF. Authors 
would like to thank Bruker Daltonics for lending a Maxis 4G. Authors thank Jim Thorn, Steven Lock and Dominique 
Mellon from Sciex separations Inc. and Yann Hebert, Pierre-Olivier Schmit and Jean-Michel Billmann from Bruker 
16 
 
Daltonics for the support. The authors would like also to express their gratitude to Dr. M. Biacchi (LSMIS, Stras-
bourg, France), P. Hammann and J. Chicher (Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France), Dr. 
E. Wagner-Rousset, , MC. Janin-Bussat and O. Colas (Centre d’Immunologie Pierre Fabre, St Julien en Genevois, 
France) for helpful discussions around antibody structural characterization by LC-MS. This work was supported by 
the CNRS (UMR 7140), the University of Strasbourg and a doctoral fellowship from the General Council of Mayotte 
to NS.
 
References 
[1] R.V.J. Chari, Targeted cancer therapy: Conferring specificity to cytotoxic drugs, Accounts Chem. Res., 41 (2008) 98-107. 
[2] S. Ornes, Antibody-drug conjugates, P. Natl. acad. Sci. USA, 110 (2013) 13695-13695. 
[3] P. Sapra, B. Shor, Monoclonal antibody-based therapies in cancer: Advances and Challenges, Pharmacol. Therapeut., 138 
(2013) 452-469. 
[4] A. Beck, J.M. Reichert, Antibody-drug conjugates, Mabs, 6 (2014) 15-17. 
[5] R.S. Zolot, S. Basu, R.P. Million, Antibody-drug conjugates, Nat. Rev. Drug Discov., 12 (2013) 259-260. 
[6] A. Beck, J.F. Haeuw, T. Wurch, L. Goetsch, C. Bailly, N. Corvaia, The Next Generation of Antibody-drug Conjugates Comes 
of Age, Discov. Med., 53 (2010) 329-339. 
[7] A. Younes, N.L. Bartlett, J.P. Leonard, D.A. Kennedy, C.M. Lynch, E.L. Sievers, A. Forero-Torres, Brentuximab Vedotin (SGN-
35) for Relapsed CD30-Positive Lymphomas, New Engl. J. Med., 363 (2010) 1812-1821.  
[8] S. Verma, D. Miles, L. Gianni, I.E. Krop, M. Welslau, J. Baselga, M. Pegram, D.Y. Oh, V. Dieras, E. Guardino, L. Fang, M.W. Lu, 
S. Olsen, K. Blackwell, E.S. Grp, Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer, New Engl. J. Med., 367 
(2012) 1783-1791. 
[9] U. Iyer, V.J. Kadambi, Antibody drug conjugates - Trojan horses in the war on cancer, J. Pharmacol. Toxicol. Meth., 64 (2011) 
207-212. 
[10] S. Krapp, Y. Mimura, R. Jefferis, R. Huber, P. Sondermann, Structural analysis of human IgG-Fc glycoforms reveals a 
correlation between glycosylation and structural integrity, J. Mol. Biol., 325 (2003) 979-989. 
[11] R. Jefferis, Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action, Trends Pharmacol. 
Sci., 30 (2009) 356-362. 
[12] A. Beck, F. Debaene, H. Diemer, E. Wagner-Rousset, O. Colas, A.V. Dorsselaer, S. Cianférani, Cutting-edge mass 
spectrometry characterization of originator, biosimilar and biobetter antibodies, J Mass Spectrom., 50 (2015) 285-297. 
[13] M. Biacchi, R. Gahoual, N. Said, A. Beck, E. Leize-Wagner, Y.-N. François, Glycoform Separation and Characterization of 
Cetuximab Variants by Middle-up Off-Line Capillary Zone Electrophoresis-UV/Electrospray Ionization-MS, Anal. Chem., 87 
(2015) 6240-6250. 
[14] D.R. Stoll, D.C. Hannes, J. Danforth, E. Wagner, D. Guillarme, S. Fekete, A. Beck, Direct Identification of Rituximab Main 
Isoforms and Subunit Analysis by Online Selective Comprehensive Two-Dimensional Liquid Chromatography-Mass 
Spectrometry, Anal. Chem., 87 (2015) 8307-8315. 
[15] F. Debaene, A. Boeuf, E. Wagner-Rousset, O. Colas, D. Ayoub, N. Corvaia, A. Van Dorsselaer, A. Beck, S. Cianferani, 
Innovative Native MS Methodologies for Antibody Drug Conjugate Characterization: High Resolution Native MS and IM-MS 
for Average DAR and DAR Distribution Assessment, Anal. Chem., 86 (2014) 10674-10683. 
[16] Y.-N. François, M. Biacchi, N. Said, C. Renard, A. Beck, R. Gahoual, E. Leize-Wagner, Characterization of cetuximab Fc/2 
dimers by off-line CZE-MS, Anal. Chim. Acta, 908 (2016) 168-176. 
[17] A. Beck, E. Wagner-Rousset, D. Ayoub, A. Van Dorsselaer, S. Sanglier-Cianférani, Characterization of Therapeutic 
Antibodies and Related Products, Anal. Chem., 85 (2013) 715-736.. 
[18] M.-C. Janin-Bussat, M. Dillenbourg, N. Corvaia, A. Beck, C. Klinguer-Hamour, Characterization of antibody drug conjugate 
positional isomers at cysteine residues by peptide mapping LC-MS analysis, J. Chromatogr. B, 981 (2015) 9-13. 
[19] D. Firth, L. Bell, M. Squires, S. Estdale, C. McKee, A rapid approach for characterization of thiol-conjugated antibody–drug 
conjugates and calculation of drug–antibody ratio by liquid chromatography mass spectrometry, Anal. Biochem., 485 (2015) 
34-42 
17 
 
[20] R. Gahoual, J.-M. Busnel, A. Beck, Y.-N. François, E. Leize-Wagner, Full Antibody Primary Structure and Microvariant 
Characterization in a Single Injection Using Transient Isotachophoresis and Sheathless Capillary Electrophoresis–Tandem Mass 
Spectrometry, Anal. Chem., 86 (2014) 9074-9081. 
[21] R. Gahoual, M. Biacchi, J. Chicher, L. Kuhn, P. Hammann, A. Beck, E. Leize-Wagner, Y.N. Francois, Monoclonal antibodies 
biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry, Mabs, 
6 (2014) 1464-1473. 
[22] R. Gahoual, A. Beck, Y.-N. François, E. Leize-Wagner, Independent highly sensitive characterization of asparagine 
deamidation and aspartic acid isomerization by sheathless CZE-ESI-MS/MS, J Mass Spectrom., 51 (2016) 150-158. 
[23] J.A. Francisco, C.G. Cerveny, D.L. Meyer, B.J. Mixan, K. Klussman, D.F. Chace, S.X. Rejniak, K.A. Gordon, R. DeBlanc, B.E. 
Toki, C.L. Law, S.O. Doronina, C.B. Siegall, P.D. Senter, A.F. Wahl, cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E 
conjugate with potent and selective antitumor activity, Blood, 102 (2003) 1458-1465. 
[24] E. Oflazoglu, K.M. Kissler, E.L. Sievers, I.S. Grewal, H.P. Gerber, Combination of the anti-CD30-auristatin-E antibody-drug 
conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma, Brit. J. Haematol., 142 (2008) 
69-73. 
[25] J.F. Valliere-Douglass, W.A. McFee, O. Salas-Solano, Native Intact Mass Determination of Antibodies Conjugated with 
Monomethyl Auristatin E and F at Interchain Cysteine Residues, Anal. Chem., 84 (2012) 2843-2849. 
[26] J. Chen, S. Yin, Y. Wu, J. Ouyang, Development of a Native Nanoelectrospray Mass Spectrometry Method for 
Determination of the Drug-to-Antibody Ratio of Antibody–Drug Conjugates, Anal. Chem., 85 (2013) 1699-1704. 
[27] R. Gahoual, J.M. Busnel, P. Wolff, Y.N. Francois, E. Leize-Wagner, Novel sheathless CE-MS interface as an original and 
powerful infusion platform for nanoESI study: from intact proteins to high molecular mass noncovalent complexes, Anal. 
Bioanal. Chem., 406 (2014) 1029-1038. 
[28] B. Wang, A.C. Gucinski, D.A. Keire, L.F. Buhse, M.T. Boyne, Structural comparison of two anti-CD20 monoclonal antibody 
drug products using middle-down mass spectrometry, Analyst, 138 (2013) 3058-3065. 
[29] Z.Q. Zhang, H. Pan, X.Y. Chen, mass spectrometry for structural characterization of therapeutic antibodies, Mass 
Spectrom. Rev., 28 (2009) 147-176. 
[30] A. Wakankar, Y. Chen, Y. Gokarn, F.S. Jacobson, Analytical methods for physicochemical characterization of antibody drug 
conjugates, mAbs, 3 (2011) 161-172. 
[31] S. Fekete, D. Guillarme, P. Sandra, K. Sandra, Chromatographic, Electrophoretic, and Mass Spectrometric Methods for the 
Analytical Characterization of Protein Biopharmaceuticals, Anal. Chem., 88(1) (2016) 480-507. 
[32] Z. Kalman-Szekeres, M. Olajos, K. Ganzler, Analytical aspects of biosimilarity issues of protein drugs, J. Pharm. Biomed. 
Anal., 69 (2012) 185-195. 
[33] L. Fornelli, D. Ayoub, K. Aizikov, A. Beck, Y.O. Tsybin, Middle-Down Analysis of Monoclonal Antibodies with Electron 
Transfer Dissociation Orbitrap Fourier Transform Mass Spectrometry, Anal. Chem., 86 (2014) 3005-3012. 
[34] A. Beck, G. Terral, F. Debaene, E. Wagner-Rousset, J. Marcoux, M.-C. Janin-Bussat, O. Colas, A. Van Dorsselaer, S. 
Cianférani, Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug 
conjugates, Expert Rev. Proteomics, 13(2) (2016) 157-183. 
[35] A. Resemann, W. Jabs, A. Wiechmann, E. Wagner, O. Colas, W. Evers, E. Belau, L. Vorwerg, C. Evans, A. Beck, D. Suckau, 
Full validation of therapeutic antibody sequences by middle-up mass measurements and middle-down protein sequencing, 
mAbs, 8(2) (2016) 318-330. 
[36] E.A. Redman, J.S. Mellors, J.A. Starkey, J.M. Ramsey, Characterization of Intact Antibody Drug Conjugate Variants Using 
Microfluidic Capillary Electrophoresis–Mass Spectrometry, Anal. Chem., 88(4) (2016) 2220-2226. 
[37] K. Wenig, L. Chatwell, U. von Pawel-Rammingen, L. Bjorck, R. Huber, P. Sondermann, Structure of the streptococcal 
endopeptidase IdeS, a cysteine proteinase with strict specificity for IgG, P. Natl. acad. Sci. USA, 101 (2004) 17371-17376. 
[38] S. Flatman, I. Alam, J. Gerard, N. Mussa, Process analytics for purification of monoclonal antibodies, J. Chromatogr. B, 
848 (2007) 79-87. 
[39] R. Gahoual, A. Burr, J.M. Busnel, L. Kuhn, P. Hammann, A. Beck, Y.N. Franccois, E. Leize-Wagner, Rapid and multi-level 
characterization of trastuzumab using sheathless capillary electrophoresis-tandem mass spectrometry, Mabs, 5 (2013) 479-
490. 
[40] J.R. Junutula, H. Raab, S. Clark, S. Bhakta, D.D. Leipold, S. Weir, Y. Chen, M. Simpson, S.P. Tsai, M.S. Dennis, Y. Lu, Y.G. 
Meng, C. Ng, J. Yang, C.C. Lee, E. Duenas, J. Gorrell, V. Katta, A. Kim, K. McDorman, K. Flagella, R. Venook, S. Ross, S.D. Spencer, 
W. Lee Wong, H.B. Lowman, R. Vandlen, M.X. Sliwkowski, R.H. Scheller, P. Polakis, W. Mallet, Site-specific conjugation of a 
cytotoxic drug to an antibody improves the therapeutic index, Nat. Biotech., 26 (2008) 925-932. 
 
